Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of glucagon in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Hepatic lipid metabolism. Started May 2018; status: completed.
02
Drugs
glucagon
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03526445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526445.